Allergan Issues Statement On Specialty Pharmacy Utilization

- Company Does Not Rely On Specialty Pharmacies For The Distribution of Its Brand Products -

- 97% of Allergan U.S. Branded Sales Are Distributed Through Traditional Wholesale and Retail Channels -

- Company Has No Ownership of or Affiliation with Any Specialty Pharmacy -

- Anda is a Traditional Wholesaler, Not a Specialty Pharmacy -

Oct 21, 2015, 12:07 ET from Allergan plc

DUBLIN, Oct. 21, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), today issued the following statement regarding specialty pharmacy utilization.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

There has been recent and potentially distracting speculation regarding the use of specialty pharmacies for the distribution of pharmaceutical products by certain pharmaceutical companies. Regarding the commercial distribution of Allergan's products, the Company does not rely on specialty pharmacies for the distribution of its products. The Company stated that approximately three percent of Allergan U.S. Branded sales are distributed through unaffiliated specialty pharmacies, the majority of which are unique specialty products, namely BOTOX® Therapeutic and ZENPEP®.

The Anda Distribution segment is a traditional pharmaceutical wholesaler with no specialty pharmacy capabilities or licensing. 

Forward-Looking Statement

Statements contained in this communication that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:                                         

Allergan
Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Mark Marmur
(862) 261-7558

SOURCE Allergan plc



RELATED LINKS

http://www.allergan.com